COMPANY

Ensoma

HQ: Boston, MA source · ensoma.com ↗ · New England

Keywords: oncology hematology X-linked chronic granulomatous disease sickle cell disease solid tumors Chronic Granulomatous Disease Related Donors Donating PBSC to a Family Member Acute Myelogenous Leukemia Acute Lymphoblastic Leukemia Myelodysplastic Syndrome Renal Insufficiency MGTA-145 EN-374

Location: Boston, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

6Trials (company is sponsor)

Raises and deals from press releases

Raise Undisclosed round · $53M · announced Sep 22, 2025 Company release ↗
Source quote
- Sep 22, 2025 · Company release ↗
  “Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline Company’s Phase 1/2 Clinical Trial of EN-374 in X-linked Chronic Granulomatous Disease is Now Open for Patient Enrollment BOSTON”

Raises announced in these releases: $53M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Sep 22, 2025 Raise Undisclosed round · $53M source ↗
Aug 5, 2025 Trial start Phase 1/Phase 2: Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease source ↗
Nov 18, 2024 Trial start —: Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease source ↗
Jun 24, 2022 Trial start Phase 2: Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease source ↗
Jun 16, 2021 Trial start Phase 2: MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies source ↗
Nov 7, 2019 Trial start Phase 1: Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment source ↗
Apr 22, 2019 Trial start Phase 1: Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor source ↗

Upcoming milestones

2026-12 (ESTIMATED) · · Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease · NCT06605378
2027-12 (ESTIMATED) · Phase 1/Phase 2 · Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease · NCT06876363

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT06876363	Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease	Phase 1/Phase 2	Active, not recruiting	Aug 5, 2025	2027-12 (estimated)
NCT06605378	Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease	Not listed	Recruiting	Nov 18, 2024	2026-12 (estimated)
NCT05445128	Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease	Phase 2	Terminated	Jun 24, 2022	Dec 8, 2022 (actual)
NCT04762875	MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies	Phase 2	Terminated	Jun 16, 2021	Sep 14, 2021 (actual)
NCT03932864	Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor	Phase 1	Completed	Apr 22, 2019	Feb 25, 2020 (actual)
NCT04154670	Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment	Phase 1	Completed	Nov 7, 2019	Mar 24, 2020 (actual)